Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

BioStock: BioInvent is gearing up for clinical data presentations

BioInvent marked a milestone in the third quarter of 2023 with the recruitment of the first patient for the BI-1808 single-agent phase IIa study. BI-1808, a potential novel checkpoint inhibitor, positions BioInvent at the forefront of harnessing the value of TNFR2 in cancer therapy. Meanwhile, the company is preparing for clinical data presentations of BI-1808 at SITC in San Diego, California and of BI-1607 at SABC in San Antonio, Texas.Read the article at biostock.se: https://www.biostock.se/en/2023/10/bioinvent-is-gearing-up-for-clinical-data-presentations/ This is a press release

Dicot AB presents Interim report Q3 2023

Press release: Uppsala, Sweden, October 31, 2023. Dicot AB (publ) publishes the interim report for the period January-September 2023. The report is available as an attached document and on the company's website www.dicot.se. Below is a summary of the report.Third quarter, June-September 2023 · Net sales amounts to KSEK 0 (0) · Earnings after financial items amounts to KSEK -8,501 (-5,073) · Earnings per share amounts to SEK -0.01 (-0.04) ”Important events are taking place for Dicot. At a research clinic in Uppsala, exactly 24 individuals have already been dosed”, says Elin

Catena announces an increase in the number of shares and votes

Catena AB (‘Catena’) has, in accordance with previously published information, increased its total number of shares and votes in October.31 October 2023 at 8.30 a.m. CET This increase is being implemented in the light of a private placement, pursuant to a resolution passed by the Board of Directors on 4 October 2023, as authorised by the general meeting of shareholders on 27 April 2023.In October 2023, Catena’s total number of shares was increased by 328,094 shares and votes. At 31 October 2023, Catena’s registered share capital totalled SEK 220,934,903.20, distributed among 50,212,478

Wyld Networks sign an agreement with PLF Australia to deploy Wyld Connect satellite IoT in rural Queensland

Queensland based PLF Australia monitor and measure water, soil, livestock, crops and on-farm weather, providing accurate management information while saving resources, time and cost. PLF will deploy Wyld Connect to deliver Internet of Things (IoT) data utilising Low Earth Orbiting satellite connectivity in rural Australia.   Vast areas of agricultural land in Australia are remotely located and have no available networks to connect IoT sensors and devices. Wyld and PLF Australia will address this lack of connectivity with Wyld’s secure sensor to satellite solutions, delivering data via

Invitation to presentation of Storskogen’s interim report for the third quarter 2023

On 7 November 2023 at 07:00 (CET), Storskogen announces its interim report for the third quarter 2023. In connection with the announcement, a presentation will be held by Daniel Kaplan, CEO, and Lena Glader, CFO, followed by a Q&A session. The presentation will be held in English and starts at 09:00 (CET).The presentation and the subsequent Q&A can be followed via webcast or telephone conference. For participation via webcast, please use the following link:Storskogen Group Q3 Report 2023 (financialhearings.com)  If

Sigrid Therapeutics Secures $4 Million in Oversubscribed Funding Round to Tap Into Booming Obesity and Diabetes Market

Both Nordic and international investors were attracted by Sigrid’s natural, non-drug alternative SiPore® technology Stockholm, Sweden, October 31[st], 2023. Sigrid Therapeutics successfully secured $4 million in an oversubscribed funding round. The investment, made by both existing and new investors, underlines the strong investor confidence in Sigrid's innovative SiPore® technology.The funds will be instrumental in accelerating the commercialisation of SiPore® across diverse markets, including medical devices, food supplements, veterinary, and oral health. SiPore21®, the company's

Catena Media announces share buybacks executed from 23 to 27 October 2023

Catena Media plc (LEI code: 549300609A73DL5C5Z86) repurchased 63,500 of its own ordinary shares (ISIN code: MT0001000109) from 23 to 27 October 2023 as part of its share buyback programme. The buyback programme was authorised by shareholders at an extraordinary general meeting on 12 July 2023 and initiated and announced by the board of directors on 17 July 2023. The programme is being carried out in accordance with the EU Market Abuse Regulation (EU) No 596/2014 ("MAR") and the Commission Delegated Regulation (EU) 2016/1052 (the "Safe Harbour Regulation"). Its purpose is to deliver

Remedy Entertainment Plc: Remedy’s financial reporting and Annual General Meeting 2024

Remedy Entertainment Plc      Stock Exchange Release     October 31, 2023, at 9:15 a.m. EET  Remedy Entertainment Plc’s financial reporting and Annual General Meeting 2024   Remedy Entertainment Plc will publish its financial reports in 2024 as follows: • Financial statements release 2023 on Friday, February 9, 2024 • Business review for January-March 2024 on Monday, April 29, 2024 • Half-year financial report for January-June 2024 on Friday, August 9, 2024 • Business review for January-September 2024 on Friday, November 1, 2024   Remedy’s Annual report 2023

Nomination Committee for Elicera therapeutics appointed

Gothenburg, October 31, 2023 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation immuno-oncological treatments based on CAR T-cells and oncolytic viruses armed with the company’s commercially available iTANK-platform, announces that representatives of the largest owners have appointed the nomination committee ahead of the Annual General Meeting  2024.   On May 10, the Annual General Meeting established rules to guide the work of the Nomination Committee. The three largest owners on September 30, 2023, were Magnus Essand, Di Yu

Anglian Water Board announces the planned retirement of Peter Simpson

Anglian Water Services ("Anglian Water" or “the Company”) announces that Peter Simpson has informed the Board that he would like to retire after a decade as Chief Executive Officer (CEO). 31 October 2023 The Board will now commence a rigorous process to appoint a successor who will lead the Company into the next five-year price review period (AMP 8). It is envisaged that this process may take around a year. Peter will continue as CEO until his successor is appointed and will support a smooth transition following their appointment. In the meantime, Peter will continue to focus on

Anglian Water Board announces the planned retirement of Peter Simpson

Anglian Water Services ("Anglian Water" or “the Company”) announces that Peter Simpson has informed the Board that he would like to retire after a decade as Chief Executive Officer (CEO). 31 October 2023 The Board will now commence a rigorous process to appoint a successor who will lead the Company into the next five-year price review period (AMP 8). It is envisaged that this process may take around a year. Peter will continue as CEO until his successor is appointed and will support a smooth transition following their appointment. In the meantime, Peter will continue to focus on

Anglian Water Board announces the planned retirement of Peter Simpson

Anglian Water Services ("Anglian Water" or “the Company”) announces that Peter Simpson has informed the Board that he would like to retire after a decade as Chief Executive Officer (CEO). 31 October 2023 The Board will now commence a rigorous process to appoint a successor who will lead the Company into the next five-year price review period (AMP 8). It is envisaged that this process may take around a year. Peter will continue as CEO until his successor is appointed and will support a smooth transition following their appointment. In the meantime, Peter will continue to focus on

Concentric wins supply contract for bespoke coolant pump with Global Market leading customer in Agriculture, Construction and Forestry

Concentric AB has been awarded a significant order to develop and supply a mechanical fixed displacement Coolant Pump for a brand-new engine platform, from a major global OEM and industry leader in the agriculture, construction and forestry equipment sector. This multi-year contract extends beyond 2034, with annual sales revenues at mature volumes of MSEK 34. This important win for Concentric stems from a long-standing relationship with this OEM customer, and serves as a testament to the exceptional quality, durability and reliability of our products. This new engine platform is

Fortaco Group acquired 100 per cent of Buisard Cabins

Fortaco Group and Buisard Cabins have joined forces. At the end of 2021, we established a strategic alliance with a minority share of Buisard and today, Fortaco acquired the remaining part of shares and reached 100 per cent ownership. Through this acquisition, Fortaco is further expanding its geographical footprint and position as one of the leading vehicle cabin technology and manufacturing partners in Europe and India. The combined net sales of our cabin business is more than 200 MEUR, while the total net sales of Fortaco Group is over 450 MEUR, including the impact of the latest M&As

Conversion of shares

According to Essity’s articles of association, owners of Class A shares have the right to have such shares converted to Class B shares. Conversion reduces the total number of votes in the company. When such a conversion has occurred, the company is obligated by law to disclose any such changes in this manner.In October, at the request of shareholders, 5,000 Class A shares were converted to Class B shares. The total number of votes in the company thereafter amounts to 1,252,719,912. The total number of registered shares in the company amounts to 702,342,489 of which 61,153,047 are Class A

Interim Report January - September 2023

“Storytel updates its 2023 guidance on the back of strong operational and financial performance during the quarter”, says Johannes Larcher, CEO, Storytel.Financial Highlights Q3 Third quarter 2023 compared to the third quarter 2022 · Streaming revenue up 13% to 842 (742) MSEK, 15% excluding Russia · Group net sales increased by 11% to 896 (806) MSEK, 12% excluding Russia · Gross profit up 13% to 352 (312) MSEK, equaling a margin of 39.3% (38.7%) · EBITDA increased by 55% to 92 (59) MSEK, equaling a margin of 10.3% (7.3%) · Operating profit of 15 (-21) MSEK · Basic and

Repurchases of shares by Concentric AB during week 43, 2023

Between 23 October 2023 and 27 October 2023 Concentric AB (LEI code 5493002G9GMTKIP3PW19) (“Concentric”) has repurchased in total 26,017 own shares (ISIN: SE0003950864) as part of the repurchase program initiated by the Board. The repurchases form part of the repurchase program of a maximum of 3,519,172 own shares for a total maximum amount of SEK 150,000,000 that Concentric announced on 26 July 2023. The repurchase program, which runs between 31 July 2023 and 31 March 2024, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 and the Commission Delegated

Orthex’s Q3 Interim report and invitation to the result presentation on 7 November 2023

Orthex Corporation, Press release, 31 October 2023 at 9.00 a.m. EETOrthex will publish its Interim report for the period January−September 2023 on Tuesday, 7 November 2023 at around 9.00 a.m. EET. Following the publication, the report will be available in pdf-format on the corporate website https://investors.orthexgroup.com/.Orthex’s CEO Alexander Rosenlew, CFO Saara Mäkelä and CMSO Hanna Kukkonen will present the report on the same day at 11.00 a.m. EET in a webcast. The webcast can be joined through this link . The webcast presentation will be held

KlaraBo extends existing loan of SEK 365 million to autumn 2026

KlaraBo has extended an existing loan of SEK 365 million until the autumn 2026. The credit margin in the loan is below KlaraBo's current average credit margin and at the same time the company extend its loan maturity to 2.4 years with the new loan, compared to 2.2 years based on figures from September 2023. KlaraBo has thus no additional credits due during the remainder of the year or during 2024. "It is very satisfying to be able to extend a loan with good terms in the current market environment. All of KlaraBo's loans are taken out via Nordic banks, which is a significant advantage in

Remedy Entertainment Plc: Business Review January-September 2023: Alan Wake 2 launched with a great reception – laying the foundation for future

Remedy Entertainment Plc | Stock exchange release | October 31, 2023 at 09:00 a.m. EET   Remedy Entertainment Plc | Business Review January–September 2023     Alan Wake 2 launched with a great reception – laying the foundation for future Higher share of own investments in game projects decreased profitability      The Business Review is unaudited. Figures in parentheses refer to the comparison period in the previous year, unless otherwise stated. Highlights from July–September 2023 •          Revenue decreased by 1.1% to EUR 7.8 (7.9) million. •

Interim report January to September 2023

Press release Sweden, Stockholm, October 31,  2023 Record high gross margin and strong development for Traffic Solutions segment Europe July-September 2023 · Net sales increased during the quarter by 0,4 % to 86,9 MSEK (86,5). The organic and currency adjusted growth amounted to -4,1 %. · Adjusted EBITDA increased during the quarter by 110,5 % and amounted to 11,0 MSEK (5,2) corresponding to an adjusted EBITDA margin by 12,6 % (6,0). · Operating profit/loss was 0,2 MSEK (-2,6), corresponding to an operating margin of 0,3 % (-3,0). · Profit/loss for the quarter was 0,2

MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT, ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENTS

  MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT, ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENTS     VANCOUVER, BC, 31 October 2023 – Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with: (i) its previously announced Common Share Subscription Agreement (the “Opensky

There are no items matching the current filter
There are no more items matching the current filter
Back to top